CAS: 49830-37-7; 1-Aminocyclopentane-1-Carbonitrile

该化合物是一种多功能的圆形微粒化合物,其特点是环戊烷环上有一个氨基和一个微微微分功能组.这一结构使该化合物成为有机合成中的宝贵中间体,特别是用于制备药品,农用化学品和特殊化学品.反应功能组的存在允许进一步衍生,使异性循环,氨酸和碳酸能够合成.其硬性环球开丙烷骨干有助于合成途径的立体化学控制.该化合物通常用于需要高纯度中间体的研究和工业应用中.适当的处理由于其功能组可能具有的再活动危害而必不可少.

结构式图片

相似化合物

16195-83-8 52-52-8 1352999-40-6

欧盟法规

C&L通报REACH预注册

上下游产品

CAS号143-33-9 氰化钠 | CAS号120-92-3 环戊酮 | CAS号7677-24-9 三甲基氰硅烷 | CAS号7664-41-7 氨 | CAS号1003-03-8 环戊胺 | CAS号75-86-5 丙酮氰醇 | CAS号151-50-8 氰化钾 | CAS号773837-37-9 sodium cyanide | CAS号67-64-1 丙酮 | CAS号17193-28-1 顺式-2-氨基-1-环戊甲酰胺 | CAS号52-52-8 环亮氨酸 | CAS号6636-92-6 Cyclopentanecar... | CAS号83521-99-7 1,3-Diazaspiro(... | CAS号91806-24-5 N-(1-氰基环戊基)-苯甲酰胺

合成工艺路线路线简述

    1-羟基环戊烷甲腈置于titanium(Iv) Isopropylate,氨,苯甲酸体系中,用 甲醇,甲基叔丁基醚 作为反应溶剂,化学反应 18.0H,以63%的收率获得产物1-氨基环戊烷甲腈
    参考文献:钛催化氰基借入反应直接用氨氨化氰醇.
    标题:钛催化氰基借入反应直接用氨氨化氰醇.
    摘要:α-氨基腈是天然产物中的重要组成部分,也是有机化学中的重要中间介质.本文中,开发了氰醇与氨的伙伴直接胺化以合成n-未保护的α-氨基腈.该反应通过钛催化的氰基借位反应进行,该反应具有较高的原子经济性和操作简单的特点.氨可耐受各种酮或醛氰醇,并且在温和的反应条件下以中等至高收率合成了n-未保护的α-氨基腈.
    DOI:10.1021/acs.Orglett.9B03194

    海关参考信息

    专利信息


    专利号:US-6211382-B1
    优先权日:1997-07-25
    标题 :Process for the preparation of 1,3-diaza-spiro (4.4) non-1-en-4-one derivatives and 1-cyano-1-acylaminocyclopentane intermediates
    发明人:HUSZAR CSABA; KIS-TAMAS ATTILA; NEMETH ATTILA; NAD ZSUZSANNA; MAKOVI ZOLTAN; GAJARY ANTAL; KOLLAR ENDRE; ARANYOSI PETER; GYUERE KAROLY; MESZAROS ISTVAN; HARI ZSUZSANNA CSETRIN; SUPIC ATTILA; ZRINYI ILONA DERVALICSNE; DUBOVSZKI KATALIN; PALIN LAJOSNE; KARASH AGNES; BOGNAR ERZSEBET
    权利人:SANOFI SYNTHELABO
    摘要:Process for the preparation of compounds of formula (I) wherein R means hydrogen atom, or C1-6 alkyl group, or C7-12 aralkyl group or phenyl group, characterised in that a) the compound of formula (III) is reacted with a compound of formula (IV) wherein X means halogen atom or C1-5 alkoxy group or hydroxyl group, and the resulting compound of formula (II) is transformed, in a reaction medium with pH above 7, into the compound of formula (I) or b) the compound of formula (III) is reacted with an anhydride of general formula (V) and the resulting compound of formula (II) transformed, in a reaction medium with pH above 7, into the compound of formula (I), or c) a compound of formula (II) is transformed, in a reaction medium with pH above 7, into the compound of formula (I), and if desired, the resulting compounds of formula (I), before or after isolation, are transformed into acid addition salts, or the compounds of formula (I) are liberated from their acid addition salts. Thus a process for the preparation of intermediates useful in synthesis of angiotensin II antagonists is disclosed.

    专利号:US-6239286-B1
    优先权日:1997-07-25
    标 题:Process for the preparation of 1,3-diaza-spiro (4.4) non-1-en-4-one derivatives and 1-cyano-1-acylamino-cyclopentane intermediates
    发明人:KIS-TAMAS ATTILA; HUSZAR CSABA; CASTRO BERTRAND; NEMETH ATTILA; ARANYOSI PETER; GYUERE KAROLY; MESZAROS ISTVAN; ZRINYI ILONA DERVALICSN; DUBOVSZKI KATALIN; PALI LAJOSNE; GAJARY ANTAL; SUPIC ATTILA; NAD ZSUZSANNA; MAKOVI ZOLTAN; KOLLAR ENDRE; HARI ZSUZSANNA CSETRIN; KARASZA GN; BOGNAR ERZSEBET
    权利人:SANOFI SYNTHELABO
    摘要:Process for the preparation of compounds of formula (I) wherein R means hydrogen atom, or C1-6 alkyl group, or C7-12 aralkyl group or phenyl group, characterised in that: a) the compound of formula (III) is reacted with a compound of formula (IV) wherein X means halogen atom or C1-5 alkoxy group or hydroxyl group and the resulting compound of formula (II) is transformed in the presence of an oxidising agent in a reaction medium with pH above 7, into the compound of formula (I), or b) the compound of formula (III) is reacted with an anhydride of general formula (V) and the resulting compound of formula (II) transformed in the presence of an oxidising agent, in a reaction medium with pH above 7, into the compound of formula (I), or c) a compound of formula (II) is transformed in the presence of an oxidising agent, in a reaction medium with pH above 7, into the compound of formula (I), and if desired, the resulting compounds of formula (I), before or after isolation, are transformed into acid addition salts, or the compounds of formula (I) are liberated from their acid addition salts. Thus a process for the preparation of intermediates useful in synthesis of angiotensin II antagonists is disclosed.

    专利号:CN-102285923-A
    优先权日:2011-08-02
    标 题 :'One-pot' synthesis of irbesartan intermediate

    专利号:US-8129411-B2
    优先权日:2005-12-30
    标题:Organic compounds
    发明人:EHARA TAKERU; GROSCHE PHILIPP; IRIE OSAMU; IWAKI YUKI; KANAZAWA TAKANORI; KAWAKAMI SHIMPEI; KONISHI KAZUHIDE; MOGI MUNETO; SUZUKI MASAKI; YOKOKAWA FUMIAKI
    权利人:EHARA TAKERU; GROSCHE PHILIPP; IRIE OSAMU; IWAKI YUKI; KANAZAWA TAKANORI; KAWAKAMI SHIMPEI; KONISHI KAZUHIDE; MOGI MUNETO; SUZUKI MASAKI; YOKOKAWA FUMIAKI; NOVARTIS AG
    摘要:The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. n The compounds have the formula I′ n nwherein R1, R2, T, R3 and R4 are as defined in the specification.

    专利号:CN-102050761-A
    优先权日:2010-12-10
    标 题 :Key intermediate of irbesartan and its synthesis method and method for synthesizing irbesartan from the intermediate
    上海予利生物科技股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.yurlichem.com
    企业联系电话:021-37285141👤
    📞上海予利生物科技股份有限公司 ⚠️参考联系方式
    联系人:严经理
    电话:021-37285141
    手机:15000957566
    传真:021-37285142
    邮箱:yurlichem@hotmail.com
    通信地址: 上海市金山区秋实路688号F楼208室
    邮编: 201512
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:上海市金山区秋实路688号F楼208室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D., Pharmaceutical Substances[Online], Thieme: Stuttgart, (2003).
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知